Clinical Trial Search

Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio

Primary: Area Under the Concentration-time Curve From 0 to Infinity (AUC0-∞) After a Single Oral Dose of Vibegron 100 mg — 6337.17; 7137.53; 5156.07; 3466.04 nM•hr

Primary: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) — 298.982; 307.320; 257.932; 261.680 nmol*h/L…

Primary: Maximum Observed Plasma Concentration (Cmax) of Cobimetinib With and Without Itraconazole — 5.21; 16.5 nanogram per milliliter (ng/mL)

Primary: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) — 278.460; 288.709; 264.509; 268.814 nmol*h/L…

Primary: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) — 286.639; 287.696; 234.052; 221.644 nmol*h/L…

Primary: Maximum Observed Plasma Concentration (Cmax) of Ticagrelor and Its Active Metabolite AR-C124910XX. — 428; 499; 479; 520 ng/mL

Primary: Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration [AUC(0-t)] — 89.04; 100.9 nmol*h/L

Primary: Number of Participants With Serious Adverse Events (SAE) and Treatment-Emergent Adverse Events (TEAE) — 0; 0; 0; 0 Participants

Primary: Cmax: Maximum Observed Plasma Concentration for TAK-385 — 46.7; 42.0; 33.0; 52.0 ng/mL

Primary: Maximum Observed Plasma Concentration (Cmax) — 0.3880; 0.4226 IU/milliliter (IU/mL)

Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart

Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) — 0; 0; 1; 1 participants

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants

Primary: Stage 1 and 1A: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants